摘要 |
The present invention provides novel crystalline forms D1 and D2 of [R-(R*,R* )]-2-(4- fluorophenyl)-ß,d-dihydroxy-5-(l-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H- pyrrole- 1-heptanoic acid hemicalcium salt, and hydrates thereof. The crystalline forms D1 and D2 have X-ray powder diffraction peaks described in Figs. 1 and 3, respectively. Further, the present invention provides processes for preparing the crystalline forms and pharmaceutical compositions comprising the crystalline forms. The crystalline forms can be produced on a commercial scale and exhibit excellent stability. |
申请人 |
DONG-A PHARM. CO., LTD.;KIM, MOON SUNG;YOO, MOO HI;RHEE, JAE KEOL;KIM, YONG JIK;PARK, SEONG JIN;CHOI, JUN HO;SUNG, SI YOUNG;LIM, HONG GYU;CHA, DAE WON |
发明人 |
KIM, MOON SUNG;YOO, MOO HI;RHEE, JAE KEOL;KIM, YONG JIK;PARK, SEONG JIN;CHOI, JUN HO;SUNG, SI YOUNG;LIM, HONG GYU;CHA, DAE WON |